BCOP Updates 2025: Bundle

Type: Bundle•Format: On-demand

The 2025 BCOP Updates Bundle offers 7.5 BCOP CE hours and ACPE CE hours.

BCOP Updates modules are on-demand and allow you to review and complete at your convenience for up to one year following the release of the education.

The modules may be completed in any order. Each contains an ACPE Pre-Test, narrated slide deck, an ACPE and BCOP Post-Test, and a Course Evaluation. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

This bundle contains the following modules:

  • Module 1: A Joint Effort: Managing Safe Medical Marijuana Use in Oncology Patients
  • Module 2: Hope for a GENEration - Advancements in Sickle Cell Disease
  • Module 3: Using Cystatin C to Evaluate Renal Dysfunction in Patients with Malignancy & Caring for Pregnant Patients with Malignancy
  • Module 4: Becoming Comfortable in the Gray (Gy) - Radiation Oncology for Pharmacists
  • Module 5: Updates in Upper GI Cancers
  • Module 6: The Beans are Making a Scene: Updates in Renal Cell Carcinoma
  • Module 7: Updates in Carcinoma of Unknown Primary

Get the bundle

Course Learning Objectives

Authors: Ashley Sabus, PharmD, BCOP, and Erin Barthelmess Goodell, PharmD, BCOP

UAN#: 0465-0000-25-079-H01-P

Learning Objectives

  1. Review the pharmacology and pharmacokinetics of medical marijuana (MMJ) products
  2. Discuss evidence-based research surrounding the efficacy of MMJ with a specific focus on its application for supportive care in oncology patients
  3. Design a plan to minimize adverse effects associated with the use of MMJ
  4. Apply practical guidelines for cultivating safe use of MMJ in oncology patients across an interdisciplinary team, including shared insights from a hospital-wide cannabinoid education consult team

Authors: Mary Catherine Cash, PharmD, BCOP, and Elizabeth Rogers Eubanks, PharmD, MPH, BCPS, BCOP, CPP

UAN#: 0465-0000-25-080-H01-P

Learning Objectives

  1. Describe the pathophysiology of sickle cell disease (SCD) and its associated complications
  2. Analyze primary literature surrounding the efficacy and safety of L-glutamine, voxelotor, and crizanlizumab
  3. Summarize primary literature surrounding the use of exagamglogene autotemcel and lovotibeglogene autotemcel for the treatment of SCD
  4. Design an appropriate supportive care regimen for a patient receiving gene therapy for SCD
  5. Compare available treatment options for SCD

Authors: Farah Raheem, PharmD, BCOP, and Bradi L. Frei, PharmD, MSc, BCOP, BCPS

UAN#: 0465-0000-25-082-H01-P

Learning Objectives

  1. Describe the mechanism of serum creatinine elevation observed with certain targeted anticancer agents
  2. Examine Cystatin C as an alternative biomarker of estimating glomerular filtration rate and evaluating renal function in patients with malignancy
  3. Describe the physiologic changes in pregnancy that affect pharmacokinetic parameters of cancer medications, such as distribution, metabolism, and elimination
  4. Discuss the use of cancer medications and supportive care, including fertility preservation, in different trimesters of pregnancy

Authors: Emma Jones, PharmD, BCOP, and Kelly Fritz, PharmD, BCOP

UAN#: 0465-0000-25-083-H01-P

Learning Objectives

  1. Summarize the effects of radiation on both tumor and healthy cells
  2. Describe the most common radiation modalities utilized in treatment of cancer
  3. Explain the mechanisms of action and place in therapy for current FDA-approved radiopharmaceuticals
  4. Select appropriate treatment options for various radiopharmaceutical toxicities
  5. Develop a plan for radiation toxicity given a patient case

Author: Sarah K. Cimino, PharmD, BCOP

UAN#: 0465-0000-25-084-H99-P

Learning Objectives

  1. Select the best treatment regimen for a patient with esophageal squamous cell carcinoma
  2. Based on patient-specific characteristics, determine the best first-line treatment regimen for a patient with HER2+ gastric adenocarcinoma
  3. Describe claudin 18.2 and the mechanism of action of zolbetuximab
  4. Summarize ongoing clinical trials for the treatment of gastric and esophageal cancers

Authors: Kelly M. Brunk, PharmD, BCOP, and Timothy J. Schieber, PharmD, MBA

UAN#: 0465-0000-25-085-H01-P

Learning Objectives

  1. Describe the role of adjuvant immunotherapy in clear cell renal cell carcinoma (RCC)
  2. Discuss first-line treatment strategies for advanced clear cell RCC
  3. Explain subsequent-line treatment of advanced clear cell RCC, addressing the controversy of reusing immune checkpoint inhibitors
  4. Summarize treatment options for non-clear cell RCC

Author: Isabel Houlzet, PharmD, BCOP

UAN#: 0465-0000-25-086-H01-P

Learning Objectives

  1. Review carcinoma of unknown primary (CUP) and recommended systemic treatment options based on tumor histology
  2. Describe the role of molecular profiling in CUP and its potential impact in care
  3. Interpret recent clinical trial data for tumor-agonistic indications in treating patients with select tumor markers
  4. Demonstrate the importance of multidisciplinary and individualized care for this patient population

Knowledge Course for Pharmacist

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.